These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10595347)

  • 21. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
    Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A short, novel, and cheaper procedure for oligonucleotide synthesis using automated solid phase synthesizer.
    Song Q; Wang Z; Sanghvi YS
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):629-33. PubMed ID: 14565241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antisense oligonucleotides in human neuronal and astrocytic cultures.
    Sogos V; Curto M; Setzu M; Mussini I; Ennas MG; Gremo F
    Methods Enzymol; 2000; 314():247-60. PubMed ID: 10565018
    [No Abstract]   [Full Text] [Related]  

  • 24. Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates.
    Duff RJ; Deamond SF; Roby C; Zhou Y; Ts'o PO
    Methods Enzymol; 2000; 313():297-321. PubMed ID: 10595363
    [No Abstract]   [Full Text] [Related]  

  • 25. Intracellular distribution of digoxigenin-labeled phosphorothioate oligonucleotides.
    Tarrasón G; Bellido D; Eritja R; Vilaró S; Piulats J
    Methods Enzymol; 2000; 313():257-68. PubMed ID: 10595360
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
    Agrawal S; Temsamani J; Tang JY
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of cancer gene functions through gene inhibition with antisense oligonucleotides.
    Robinson-Benion C; Jensen RA; Holt JT
    Methods Enzymol; 2000; 314():499-506. PubMed ID: 10565035
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of plasminogen activator inhibitor release in endothelial cell cultures by antisense oligodeoxyribonucleotides with a 5'-end lipophilic modification.
    Kobylańska A; Pluskota E; Swiatkowska M; Wójcik M; Cierniewska-Cieślak A; Krakowiak A; Boczkowska M; Pawłowska Z; Okruszek A; Koziołkiewicz M; Cierniewski CS; Stec WJ
    Acta Biochim Pol; 1999; 46(3):679-91. PubMed ID: 10698276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug treatment for Crohn's disease.
    Yacyshyn BR
    Lancet; 1998 Aug; 352(9129):743. PubMed ID: 9729027
    [No Abstract]   [Full Text] [Related]  

  • 32. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides.
    Brown-Driver V; Eto T; Lesnik E; Anderson KP; Hanecak RC
    Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):145-54. PubMed ID: 10355821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.
    Wahlestedt C; Salmi P; Good L; Kela J; Johnsson T; Hökfelt T; Broberger C; Porreca F; Lai J; Ren K; Ossipov M; Koshkin A; Jakobsen N; Skouv J; Oerum H; Jacobsen MH; Wengel J
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5633-8. PubMed ID: 10805816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue.
    Geary RS; Matson J; Levin AA
    Anal Biochem; 1999 Oct; 274(2):241-8. PubMed ID: 10527522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antisense constructs, therapeutics of the future?].
    Van Aerschot A
    Verh K Acad Geneeskd Belg; 2000; 62(6):565-601. PubMed ID: 11196580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific inhibition of hepatitis C viral gene expression by non-polar (phenylalkyl)phosphonates.
    Amberg S; Tamke A; Caselmann WH; Engels JW
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1631-4. PubMed ID: 14565483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiology and molecular biology brought to single-cell level.
    Lledo PM; Desmaisons D; Carleton A; Vincent JD
    Methods Enzymol; 2000; 313():143-56. PubMed ID: 10595353
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups.
    MacKellar C; Graham D; Will DW; Burgess S; Brown T
    Nucleic Acids Res; 1992 Jul; 20(13):3411-7. PubMed ID: 1630912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.